🌍⚖️ Government rejects Duplomb law to reauthorize acetamiprid
Oneliner
The French government has decided not to support Senator Laurent Duplomb's new bill to reintroduce acetamiprid, a banned pesticide, following a petition that gathered over 2 million signatures. The Constitutional Council previously struck down provisions of the Duplomb law for lacking environmental safeguards. Despite this, Duplomb plans to submit a revised bill, but government backing is unlikely amid strong public opposition.
Key points
- The French government will not support the reintroduction of acetamiprid, a banned pesticide.
- A petition against the Duplomb law gathered over 2 million signatures, reflecting public opposition.
- The Constitutional Council previously struck down provisions of the law for lacking environmental safeguards.
- Senator Laurent Duplomb plans to submit a revised bill, but government backing is unlikely.
Links
- RFI: Why France's agriculture law may not help the farmers it claims to defend
- BFMTV: "On ne peut pas faire comme si une pétition n'avait pas réuni 2 millions de signataires": le gouvernement ne soutiendra pas la nouvelle loi Duplomb qui veut remettre sur la table un insecticide interdit
- Le Figaro: Le gouvernement ne soutiendra pas le retour de la loi Duplomb visant à réautoriser l’acétamipride
Facts
- The Duplomb law was passed on 8 July 2025.
- Over 2 million signatures were collected on the petition against the law.
- The Constitutional Council ruled against the reintroduction of acetamiprid in August 2025.
- The government spokesperson stated the need to acknowledge public concern regarding pesticide use.
Quotes
- You cannot pretend that a petition did not gather 2 million signatories. We must also hear the concern of those French citizens who alerted us — Maud Bregeon
- No serious study has shown that acetamiprid is carcinogenic — Laurent Duplomb
Article
🔒 Access the full content
Upgrade to unlock the full distillation, context, and source trail.
Already subscribed? Open today’s newsletter and follow your personal access link.
